The manufacturing lot evaluation confirmed all devices met specifications prior to release.The devices remain implanted in the patient and were not returned, no evaluation completed.At the completion of the clinical assessment, the type 3b endoleak was refuted.Instead, this endoleak was determined to be a type 1b.Additionally, there was evidence to support the reported intragraft thrombus and the secondary procedure with implantation of an iliac extension (ovation).Although, the limb was reported to be positioned with the distal end into the vessel wall in a tortuous native anatomy, the most likely cause of the loss of seal could not be determined due to lack of relevant medical information.The final patient disposition was reported to be discharged from the hospital.Endologix continues to investigate this event and similar events to ensure the highest quality and patient safety.These types of events will be monitored and trended as part of the quality system.(b)(4).
|